MLYS
SinkerMineralys Therapeutics, Inc. · Healthcare · United States · $1.8B cap · $27.8M/day traded
$15.33 -1.1% · close 13 Nov · scored 14 Nov
Sinker: Weak business, rich price and weak momentum. Nothing here to keep it afloat.
As of 14 Nov 2026, the MoatMap Score for Mineralys Therapeutics, Inc. (MLYS) is 6/100, ranked against 25,000+ stocks in 38 markets (Quality 29, Value 28, Momentum 18, each scored against its sector).
Does the score work? Each tenth of the ranking, tracked monthly. See the record →
ABOUT MINERALYS THERAPEUTICS, INC.
Read
Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapies for hypertension and cardiorenal diseases, with its lead candidate lorundrinerant. Its proprietary drug candidate targets a novel mechanism of action (aldosterone synthase inhibition) for uncontrolled hypertension, addressing a significant unmet medical need. The company is developing a potential first-in-class treatment that could offer a new therapeutic option for patients with high blood pressure and related conditions.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Income and shares | ||||||||||
| Revenue | — | — | — | — | — | — | — | — | 79.2M | — |
| Net margin | — | n/m | n/m | n/m | n/m | — | — | — | — | — |
| EPS | -3.77 | -0.34 | -0.93 | -3.66 | -2.29 | — | -4.30 | -4.59 | -2.60 | — |
| Share count | — | 88.2M | 88.2M | 49.8M | 81.5M | -2.6% | 88.6M | — | — | — |
| Balance sheet | ||||||||||
| Debt | — | — | — | — | — | — | — | — | — | — |
| Equity | — | -52.3M | 241.2M | 191.3M | 646.7M | 63.8% | — | — | — | — |
| Debt/equity | — | — | — | — | — | — | — | — | — | — |
| Cash flow | ||||||||||
| Op. cash flow | — | -29.2M | -81.2M | -166.3M | -142.4M | — | -153.0M | — | — | — |
| Cash flow margin | — | n/m | n/m | n/m | n/m | — | — | — | — | — |
| Investing CF | — | -21.8M | -160.5M | 115.0M | -389.8M | — | — | — | — | — |
| Financing CF | — | 128.0M | 203.2M | 116.1M | 591.0M | — | — | — | — | — |
Made a new 52-week low in the latest session, 67% below its 52-week high. The fall has not stopped yet.
Swung more than 76% of stocks we rank over the past year (volatility 62% a year).
How this is worked out
The Price check reads only the chart, the price side of the Momentum score in words; it is not the MoatMap Score.
- Still falling (this stock): It set a new 52-week low in the last two weeks, after a deep fall.
- Finding a floor: It fell hard, but has set no new low for more than two weeks.
- Turning up: It has climbed off its low and is back above a rising 50-day average.
- In an uptrend: It is near its 52-week high and above its 200-day average.
- No clear trend: None of the above: no recent deep fall and no steady climb.
- No read yet: Not enough price history yet: it needs a year of trading.
In past US falls, waiting for Turning up cut the chance of another 20% drop from 42% to 33%. Returns were no better, and 33% of turns failed.
The exact rules
Still falling is a new 52-week low in the last two weeks, at least 25% below the high, with the low set after the high. Finding a floor is the same fall with no new low in the last two weeks. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average, with the 50-day average above the 200-day, and within 15% of the high. No clear trend is everything else. No read yet is under 252 trading days of history, or missing data. A new state shows once it has held for three trading days.
In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn (the Turning up rule above) cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.
What it measures: how much the price moved day to day over the past year, scaled to a yearly figure (annualised volatility) and ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of MLYS are excluded.
| Ticker | Company | Mkt Cap | Score |
|---|---|---|---|
| MLYS | Mineralys Therapeutics, Inc.(you) | $1.8B | 6 |
| VERA | Vera Therapeutics, Inc. | $2.0B | 6 |
| ADRX | ADARx Pharmaceuticals, Inc. | $1.9B | 9 |
| GENB | Generate Biomedicines, Inc. | $1.6B | 5 |
| NTLA | Intellia Therapeutics, Inc. | $1.6B | 7 |
| LYCA | Lycia Therapeutics, Inc. | $1.6B | 7 |
| RCUS | Arcus Biosciences, Inc. | $2.3B | 6 |
| STOK | Stoke Therapeutics, Inc. | $1.6B | 9 |
| OCUL | Ocular Therapeutix, Inc. | $1.4B | 4 |
| INBX | Inhibrx Biosciences, Inc. | $1.4B | 5 |
Peer medians: ROE -29.9% · P/E 26.6x · Gross margin 63.3%
Company Deep Dive
A 10,000-word report: the business and its segments, what management promised on earnings calls and whether it delivered, the competition, and how things could turn out.